Patents by Inventor Michael Melnick

Michael Melnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240134494
    Abstract: A system facilitates real-time user interactions in a virtual environment of a user application accessible by multiple computing devices. System instructions include receiving a set of defined topics including a defined topic from a first computing device of the computing devices. The instructions include receiving, from at least one of the computing devices, data representing machine-readable text converted from a verbal conversation between two or more users in the virtual environment. The instructions include identifying a set of topics from the data representing machine-readable text. The instructions include comparing the identified set of topics from the data representing machine-readable text to the set of defined topics. The instructions include, in response to detecting a match between a topic of the identified set of topics and the defined topic of the set of defined topics, transmitting, to the first computing device, a notification of the matching defined topic.
    Type: Application
    Filed: January 3, 2024
    Publication date: April 25, 2024
    Applicant: Charles Schwab & Co., Inc.
    Inventors: Jeffrey Michael FREISTHLER, Justin Wayne WEBSTER, Christopher Nathan MELNICK, Bryan EDELMAN, Nathan Ralph HOGGE, Jacob Patrick SULLIVAN
  • Patent number: 9359623
    Abstract: Provided herein are methods and compositions for the production of renewable fatty acids from photosynthetic prokaryotic microorganisms, such as a blue green algae, any specie of the phylum Cyanophyta, a chloroplast of a green algae and/or a Cyanobacterium. Engineered or natural strains of these organisms or organelles can be used to produce both saturated and unsaturated fatty acids with variable chain length specificity from 8-18 carbons. The fatty acids can then be secreted into the culture medium, allowing for rapid, continuous and efficient separation of fatty acid product without harvesting of cell mass.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: June 7, 2016
    Assignee: The Regents of the University of California
    Inventors: Steve A. Kay, Ewa Lis, Susan Golden, Michael Melnick, Dawn M. Adin, James W. Golden
  • Patent number: 8624034
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: January 7, 2014
    Assignee: Pfizer Inc.
    Inventors: Usa Reilly, Michael Melnick, Matthew F. Brown, Mark S. Plummer, Justin Montgomery, Ye Che, Loren Price
  • Publication number: 20120232083
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Inventors: Usa REILLY, Michael MELNICK, Matthew F. BROWN, Mark S. PLUMMER, Justin MONTGOMERY, Ye CHE, Loren PRICE
  • Publication number: 20120184004
    Abstract: Provided herein are methods and compositions for the production of renewable fatty acids from photosynthetic prokaryotic microorganisms, such as a blue green algae, any specie of the phylum Cyanophyta, a chloroplast of a green algae and/or a Cyanobacterium. Engineered or natural strains of these organisms or organelles can be used to produce both saturated and unsaturated fatty acids with variable chain length specificity from 8-18 carbons. The fatty acids can then be secreted into the culture medium, allowing for rapid, continuous and efficient separation of fatty acid product without harvesting of cell mass.
    Type: Application
    Filed: July 22, 2010
    Publication date: July 19, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Steve A. Kay, Ewa Lis, Susan Golden, Michael Melnick, Dawn M. Adin, James W. Golden
  • Patent number: 7179918
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: February 20, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Benjamin J. Burke, Tanya M. Jewell, David J. Kucera, Maria Angelica Linton, Lennert J. Mitchell, Jr., Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Jeffrey J. Machak, Tod Holler, Sean T. Murphy, Michael Melnick, Vara Prasad Josyula
  • Publication number: 20070021354
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Application
    Filed: June 9, 2006
    Publication date: January 25, 2007
    Inventors: Stacie Canan Koch, Therese Alexander, Benjamin Burke, Tanya Jewell, David Kucera, Maria Linton, Lennert Mitchell, Siegfried Reich, Donald Skalitzky, John Tatlock, Michael Varney, Scott Virgil, Stephen Webber, Stephen Worland, Mark Barvian, Gary Bolton, Frederick Boyer, Jeffrey Machak, Tod Holler, Sean Murphy, Michael Melnick, Vara Josyula
  • Publication number: 20050250707
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Application
    Filed: June 20, 2005
    Publication date: November 10, 2005
    Inventors: Stacie Canan Koch, Therese Alexander, Benjamin Burke, Tanya Jewell, David Kucera, Maria Linton, Lennert Mitchell, Siegfried Reich, Donald Skalitzky, John Tatlock, Michael Varney, Scott Virgil, Stephen Webber, Stephen Worland, Mark Barvian, Gary Bolton, Frederick Boyer, Jeffrey Machak, Tod Holler, Sean Murphy, Michael Melnick, Vara Josyula
  • Patent number: 6953858
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 11, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Publication number: 20030225071
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: December 4, 2003
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Fredrick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Publication number: 20030153507
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: August 14, 2003
    Inventors: Stacie S. Canan-Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Patent number: 5863950
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and possibly other anti-viral agents as ingredients, are thus suitable for the treatment of the HIV virus known to cause AIDS.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: January 26, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Siegfried H. Reich, Kathleen Lewis, Michael Melnick, Mary Ann M. Fuhry, Stephen Warren Kaldor